Bicycle Therapeutics (BCYC) Times Interest Earned (2021 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Times Interest Earned came in at -$15.16 in Q2 2026, up 53.51% YoY from -$9.88 in Q2 2025, and up 16.82% on a QoQ basis from -$18.22 in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Times Interest Earned (2021 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Times Interest Earned data on file, last reported at -$15.16 in Q2 2026.
- Quarterly Times Interest Earned rose 53.51% year-over-year to -$15.16 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$58.43 (up 46.17% YoY) and the FY2025 annual result came in at -$1.95, up 7.44% from the prior year.
- Times Interest Earned rose to -$15.16 in Q2 2026, from -$18.22 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $223.19 in Q4 2023 to a low of -$50.65 in Q4 2022.
- A 5-year average of $5.29 and a median of -$1.5 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 540.68% — and 2025, when it slumped 4005.45%.
- Tracing BCYC's Times Interest Earned over 5 years: stood at -$50.65 in 2022, then soared by 540.68% to $223.19 in 2023, then sank by 78.84% to $47.22 in 2024, then slumped by 113.95% to -$6.59 in 2025, then plunged by 130.14% to -$15.16 in 2026.
- The last three Times Interest Earned figures came in at -$15.16 (Q2 2026), -$18.22 (Q1 2026), and -$6.59 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -1,239.98 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,239.98 |
| Mar 31, 2026 | -1,364.21 |
| Dec 31, 2025 | -433.47 |
| Sep 30, 2025 | -1,489.80 |
| Jun 30, 2025 | -1,603.74 |
| Mar 31, 2025 | -1,376.55 |
| Dec 31, 2024 | -1,301.21 |
| Sep 30, 2024 | -1,934.73 |
| Jun 30, 2024 | -56.61 |
| Mar 31, 2024 | -38.63 |
| Dec 31, 2023 | -66.14 |
| Sep 30, 2023 | -62.40 |
| Jun 30, 2023 | -52.51 |
| Mar 31, 2023 | -51.74 |
| Dec 31, 2022 | -39.00 |
| Sep 30, 2022 | -36.42 |
| Jun 30, 2022 | -30.92 |
| Mar 31, 2022 | -33.48 |
| Dec 31, 2021 | -21.98 |
| Sep 30, 2021 | -17.37 |